Marla Cindy Dubinsky

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. pmc Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease
    Marla Cindy Dubinsky
    Pediatric IBD Center, Department of Pediatrics, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    World J Gastroenterol 16:2604-8. 2010
  2. pmc Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease
    Marla C Dubinsky
    Department of Pediatrics and Medicine, Inflammatory Bowel Disease Program, Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    Inflamm Bowel Dis 16:1357-66. 2010
  3. doi request reprint Management of the pregnant IBD patient
    Marla Dubinsky
    Department of Pediatrics, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Inflamm Bowel Dis 14:1736-50. 2008
  4. ncbi request reprint New patients: should children be treated differently?
    M C Dubinsky
    Pediatric IBD Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Colorectal Dis 8:15-9. 2006
  5. ncbi request reprint Monitoring of AZA/6-MP treatment in children with IBD is necessary
    Marla C Dubinsky
    Pediatric Gastroenterology, Cedars Sinai Hospital, Los Angeles, CA 90048, USA
    Inflamm Bowel Dis 9:386-8; discussion 392-3. 2003
  6. ncbi request reprint Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine
    Marla C Dubinsky
    Department of Medicine, Division of Gastroenterology, Cedars Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
    Am J Gastroenterol 98:1058-63. 2003
  7. ncbi request reprint 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease
    Marla C Dubinsky
    Division of Gastroenterology and Genetics, Department of Medicine and Pediatrics, Cedars Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
    Gastroenterology 122:904-15. 2002
  8. pmc Genome-wide association identifies multiple ulcerative colitis susceptibility loci
    Dermot P B McGovern
    Inflammatory Bowel and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    Nat Genet 42:332-7. 2010
  9. ncbi request reprint Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease
    Stephen A Geller
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Am J Surg Pathol 28:1204-11. 2004
  10. ncbi request reprint Immunogenetic phenotypes in inflammatory bowel disease
    Marla C Dubinsky
    Department of Pediatrics, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    World J Gastroenterol 12:3645-50. 2006

Detail Information

Publications31

  1. pmc Serologic and laboratory markers in prediction of the disease course in inflammatory bowel disease
    Marla Cindy Dubinsky
    Pediatric IBD Center, Department of Pediatrics, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    World J Gastroenterol 16:2604-8. 2010
    ..The knowledge of an individual's prognosis can help physicians and patients make important management decisions and aid communication on risk and benefits of disease and treatment...
  2. pmc Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease
    Marla C Dubinsky
    Department of Pediatrics and Medicine, Inflammatory Bowel Disease Program, Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    Inflamm Bowel Dis 16:1357-66. 2010
    ....
  3. doi request reprint Management of the pregnant IBD patient
    Marla Dubinsky
    Department of Pediatrics, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Inflamm Bowel Dis 14:1736-50. 2008
    ..We would like to emphasize that the information presented here must be individualized to the specific situation of each patient, their acceptance of risk, and their degree of disease severity...
  4. ncbi request reprint New patients: should children be treated differently?
    M C Dubinsky
    Pediatric IBD Center, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Colorectal Dis 8:15-9. 2006
    ..A recent case report, involving a 15-year old boy presenting with abdominal pain and bloody diarrhoea, illustrates the difficulty in correctly diagnosing IBD in children and the need for optimizing therapy to achieve treatment success...
  5. ncbi request reprint Monitoring of AZA/6-MP treatment in children with IBD is necessary
    Marla C Dubinsky
    Pediatric Gastroenterology, Cedars Sinai Hospital, Los Angeles, CA 90048, USA
    Inflamm Bowel Dis 9:386-8; discussion 392-3. 2003
  6. ncbi request reprint Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine
    Marla C Dubinsky
    Department of Medicine, Division of Gastroenterology, Cedars Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
    Am J Gastroenterol 98:1058-63. 2003
    ..The aim of this study was to determine if hypersensitivity reactions to 6-MP/AZA reoccur with 6-TG therapy...
  7. ncbi request reprint 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease
    Marla C Dubinsky
    Division of Gastroenterology and Genetics, Department of Medicine and Pediatrics, Cedars Sinai Medical Center, UCLA, Los Angeles, California 90048, USA
    Gastroenterology 122:904-15. 2002
    ..The objectives of this study were to determine whether dose escalation optimizes both 6-TGN levels and efficacy in patients failing therapy because of subtherapeutic 6-TGN levels and its effect on TPMT...
  8. pmc Genome-wide association identifies multiple ulcerative colitis susceptibility loci
    Dermot P B McGovern
    Inflammatory Bowel and Immunobiology Research Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    Nat Genet 42:332-7. 2010
    ..These data implicate approximately 30 loci in ulcerative colitis, thereby providing insight into disease pathogenesis...
  9. ncbi request reprint Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease
    Stephen A Geller
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Am J Surg Pathol 28:1204-11. 2004
    ..6-TG-related hepatotoxicity, including liver biochemistry value elevations, sinusoidal collagen deposition on electron microscopy, and veno-occlusive disease, have been described related to its use as therapy for neoplastic disease...
  10. ncbi request reprint Immunogenetic phenotypes in inflammatory bowel disease
    Marla C Dubinsky
    Department of Pediatrics, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    World J Gastroenterol 12:3645-50. 2006
    ....
  11. ncbi request reprint A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine
    Marla C Dubinsky
    Department of Pediatrics, Pediatric IBD Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Am J Gastroenterol 100:2239-47. 2005
    ..We performed a decision analysis to estimate the potential costs and effectiveness of TPMT screening and MM as disease management strategies for CD...
  12. pmc IL-23 receptor (IL-23R) gene protects against pediatric Crohn's disease
    Marla C Dubinsky
    Department of Pediatrics, Medical Genetics Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    Inflamm Bowel Dis 13:511-5. 2007
    ..It is unknown whether IL-23R is associated with IBD in children. The aim was to examine the association of IL-23R with susceptibility to IBD in pediatric patients...
  13. ncbi request reprint Optimizing immunomodulator therapy for inflammatory bowel disease
    Marla C Dubinsky
    Pediatric IBD Center, Cedars Sinai Medical Center, 8635 West 3rd Street, Suite 1165W, Los Angeles, CA 90048, USA
    Curr Gastroenterol Rep 5:506-11. 2003
    ....
  14. ncbi request reprint Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety
    Marla C Dubinsky
    Pediatric IBD Center, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Clin Gastroenterol Hepatol 2:731-43. 2004
    ..By gaining an understanding of the pharmacology and metabolism of thiopurine therapy and putting it into the clinical context, clinicians will be able to optimize thiopurine therapy in IBD...
  15. pmc Increased immune reactivity predicts aggressive complicating Crohn's disease in children
    Marla C Dubinsky
    Department of Pediatrics, IBD Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    Clin Gastroenterol Hepatol 6:1105-11. 2008
    ..The aims of this study were to determine whether immune responses and/or CARD15 variants are associated with complicated disease phenotypes and predict disease progression...
  16. pmc Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression
    Marla C Dubinsky
    Department of Pediatrics, Genetics Institute, Cedars Sinai Medical Center, Los Angeles, California, USA
    Am J Gastroenterol 101:360-7. 2006
    ..We examined the association of immune responses to microbial antigens with disease behavior and prospectively determined the influence of immune reactivity on disease progression in pediatric CD patients...
  17. ncbi request reprint A pilot study of adalimumab in infliximab-allergic patients
    Adrienne Youdim
    Department of Medicine, Division of Gastroenterology, Inflammatory Bowel Disease Center, Los Angeles, CA 90048, USA
    Inflamm Bowel Dis 10:333-8. 2004
    ..Based on these preliminary data, adalimumab may be a safe and effective substitute for infliximab-allergic patients. Individuals who have been exposed to human antibodies may be sensitized to other human antibodies such as adalimumab...
  18. ncbi request reprint Initial experience with wireless capsule enteroscopy in the diagnosis and management of inflammatory bowel disease
    William S Mow
    Inflammatory Bowel Disease Center, Los Angeles, California, USA
    Clin Gastroenterol Hepatol 2:31-40. 2004
    ..The aim of this study is to assess the clinical utility of WCE in the evaluation of patients with known or suspected inflammatory bowel disease (IBD)...
  19. ncbi request reprint Clinical perspectives in Crohn's disease. Serologic and prognostic biomarkers: who, when, and how?
    Marla C Dubinsky
    Pediatric Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, California, USA
    Rev Gastroenterol Disord 7:S3-7. 2007
    ..Determining the factors that can predict the progression from uncomplicated to complicated disease states may stratify patients into at-risk populations and have an impact on their ultimate therapeutic management...
  20. ncbi request reprint 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients
    Marla C Dubinsky
    Pediatric Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, 8635 West Third Street, Suite 1165W, Los Angeles, California 90048, USA
    Gastroenterology 125:298-303. 2003
    ..The aim of this study was to describe the association between 6-TG and NRH in IBD...
  21. ncbi request reprint Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab
    Konstantinos A Papadakis
    Division of Gastroenterology, Department of Medicine, Inflammatory Bowel Disease Center, 8631 W Third Street, Suite 430E, Los Angeles, CA 90048, USA
    Am J Gastroenterol 100:75-9. 2005
    ..The aim of our study was to examine the safety and efficacy of adalimumab (D2E7), a fully humanized anti-TNF-alpha Ab, in CD patients who had experienced an attenuated response to infliximab...
  22. ncbi request reprint Early nodular hyperplasia of the liver occurring with inflammatory bowel diseases in association with thioguanine therapy
    Sunita Shastri
    Department of Pathology and Laboratory Medicine, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Arch Pathol Lab Med 128:49-53. 2004
    ..Recently, 6-thioguanine has been used to treat patients with inflammatory bowel disease who have been resistant to other forms of therapy...
  23. ncbi request reprint Probiotics in pediatric inflammatory bowel diseases
    Ajay S Gulati
    Department of Pediatrics, Division of Pediatric Gastroenterology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Curr Gastroenterol Rep 11:238-47. 2009
    ..This article examines the currently available published trials studying probiotics for the treatment of IBD, with particular emphasis on their role in pediatric IBD patients...
  24. ncbi request reprint Suspected inflammatory bowel disease--the clinical and economic impact of competing diagnostic strategies
    Marla C Dubinsky
    Department of Pediatrics, Cedars Sinai Medical Center, University of California Los Angeles School of Medicine, USA
    Am J Gastroenterol 97:2333-42. 2002
    ....
  25. ncbi request reprint Severe colitis in children
    Subra Kugathasan
    Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA
    J Pediatr Gastroenterol Nutr 41:375-85. 2005
  26. ncbi request reprint Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn
    Eric A Vasiliauskas
    Inflammatory Bowel Disease Center, Division of Gastroenterology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Clin Gastroenterol Hepatol 4:1255-8. 2006
    ..As a result of heightened maternal concern triggered by recent labeling changes, infliximab levels were measured in the newborn of a mother treated with infliximab...
  27. ncbi request reprint Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease
    Jacob Spivak
    Division of Colon and Rectal Surgery, Department of Surgery, Inflammatory Bowel Disease Center, Cedars Sinai Medical Center, Los Angeles, CA, USA
    Inflamm Bowel Dis 12:1122-30. 2006
    ..This study examines the association between clinical features and seroreactivity to these microbial and auto-antigens in predicting a clinical response to fecal diversion...
  28. ncbi request reprint Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America
    Athos Bousvaros
    J Pediatr Gastroenterol Nutr 44:653-74. 2007
    ....
  29. doi request reprint Disease perceptions among people with Crohn's disease
    Sunanda V Kane
    Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA
    Inflamm Bowel Dis 14:1097-101. 2008
    ..We sought to characterize CD patient perceptions of both overall disease course and current symptomatology based on an objective symptom scale and to explore the relationship between perceptions and current symptoms...
  30. ncbi request reprint Determination of serologic and genetic markers aid in the determination of the clinical course and severity of patients with IBD
    Shane M Devlin
    Inflammatory Bowel Disease Center, The University of Calgary, Calgary, Alberta, Canada
    Inflamm Bowel Dis 14:125-8; discussion 132-3. 2008
  31. ncbi request reprint Challenges in pediatric inflammatory bowel disease
    Athos Bousvaros
    Children s Hospital Boston and Harvard Medical School, Boston, MA 02115, USA
    Inflamm Bowel Dis 12:885-913. 2006
    ..At the conclusion of the meeting, investigators discussed the formation of a multicenter collaborative network to advance clinical and basic research in the field...